Opoc, John Mark A.
HRN: 22-75-31 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/26/2023
CLINDAMYCIN 300MG (CAP)
03/26/2023
04/02/2023
PO
300
TID
PCAP C; TB Presumptive; Scrofuloderma
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes